This article presents the case of a patient with recurrent glioblastoma who questions whether he can or should pay for treatment with bevacizumab. There are differing views on the physician’s role in dealing with cost and cost-effectiveness issues for patients, but it is becoming increasingly unrealistic for physicians to disregard the cost of cancer care when making treatment recommendations. Physicians need to be able to address cost issues in order to allow individual patients to make the best informed decision about what treatment option is the most beneficial and the “best value” for them.
Address correspondence to Dr Edward Dropcho, Indiana University Medical Center, 541 Clinical Drive, Department of Neurology, CL 292, Indianapolis IN 46202, email@example.com.
Relationship Disclosure: Dr Dropcho has served as a speaker for Merck and Co., Inc. and is a member of the editorial board for Medlink Neurology.
Unlabeled Use of Products/Investigational Use Disclosure: Dr Dropcho reports no disclosure.